NCT00544180 ROSPA - Record on Satisfaction of Patients With Actonel 35 mg Once a Week Status TERMINATED Phase PHASE4
NCT00543972 Dose Escalation Safety and Pharmacokinetic Study of AVE9633 as Single Agent in Relapsed/Refractory CD33-Positive Acute Myeloid Leukemia Status TERMINATED Phase PHASE1
NCT00542165 Multicenter Prospective Study on the Changes of Sexual Function Following Treatment With Alfuzosin (Xatral XL®) in Patients With Benign Prostate Hypertrophy Status COMPLETED Phase PHASE4
NCT00541281 Safety and Efficacy Study of of Docetaxel vs Docetaxel Estramustine in Hormone Refractory Prostatic Cancer Status COMPLETED Phase PHASE2
NCT00540891 The Efficacy, Onset of Effect, and Safety of Alfuzosin Once Daily in the Treatment of Lower Urinary Tract Symptoms of Benign Prostatic Hyperplasia: A Randomized, Placebo-Controlled Trial Using an Acute International Prostate Score Status COMPLETED Phase PHASE3
NCT00540410 Cohort Study in Senegal Comparing Artesunate + Amiodaquine in the Treatment of Repeated Uncomplicated Plasmodium Falciparum Malaria Attacks Status COMPLETED Phase PHASE4
NCT00540358 A Phase 2 Trial of Standard Chemotherapy, With or Without BSI-201, in Patients With Triple Negative Metastatic Breast Cancer Status COMPLETED Phase PHASE2
NCT00539981 Immunogenicity, Safety, Reactogenicity, Efficacy, Effectiveness and Lot Consistency of FluBlok Status COMPLETED Phase PHASE3
NCT00539669 TAX + Carboplatin or Cisplatin 1st Line Post-Surgery Ovarian Status COMPLETED Phase PHASE2
NCT00538148 Telithromycin: in the Treatment of Acute Exacerbation of Chronic Bronchitis in Adult Outpatients With COPD Status COMPLETED Phase PHASE4
NCT00538018 Telithromycin, Treating Adult Outpatients With Mild to Moderate Community-acquired Pneumonia (CAP) in High Bacterial Resistance Areas Status COMPLETED Phase PHASE4
NCT00537251 32 Week, Open, Randomized, 2 Way Cross Over Multicentre Trial to Compare Safety & Efficacy of Combination of HOE901 Insulin Analogue Once Daily at Bedtime + Lispro Insulin Before Meals vs NPH Insulin (Twice a Day) + Regular in Type 1 Diabetes Mellitus Status COMPLETED Phase PHASE3
NCT00535340 An Eight-Week Study to Evaluate the Efficacy and Safety of SR58611A in Elderly Patients With Generalized Anxiety Disorder Status TERMINATED Phase PHASE3